Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.
J Clin Immunol
; 41(2): 345-355, 2021 02.
Article
en En
| MEDLINE
| ID: mdl-33263173
ABSTRACT
Although it is estimated that COVID-19 life-threatening conditions may be diagnosed in less than 11000 infected individuals below the age of 50, but the real impact of this pandemic on pediatric patients with different types of primary immunodeficiency (PID) is not elucidated. The current prospective study on a national registry of PID patients showed that with only 1.23 folds higher incidence of infections, these patients present a 10-folds higher mortality rate compared to population mainly in patients with combined immunodeficiency and immune dysregulation. Therefore, further management modalities against COVID-19 should be considered to improve the survival rate in these two PID entities using hematopoietic stem cell transplantation and immunomodulatory agents.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
4_TD
/
6_ODS3_enfermedades_notrasmisibles
/
7_ODS3_muertes_prevenibles_nacidos_ninos
Problema de salud:
2_muertes_prevenibles
/
4_covid_19
/
4_pneumonia
/
6_other_respiratory_diseases
/
7_non_communicable_diseases
Asunto principal:
Evaluación del Impacto en la Salud
/
Enfermedades de Inmunodeficiencia Primaria
/
SARS-CoV-2
/
COVID-19
Tipo de estudio:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
J Clin Immunol
Año:
2021
Tipo del documento:
Article
País de afiliación:
Irán